Baclofen and Alcohol-Dependent Patients: A Real Risk of Severe Self-Poisoning. 2017

David Boels, and Caroline Victorri-Vigneau, and Marie Grall-Bronnec, and Ali Touré, and Anais Garnier, and Alain Turcant, and Gaël Le Roux
Poison Control Center, Angers University Hospital, Angers, France.

Baclofen is often prescribed in high doses to fight cravings experienced by alcohol-dependent patients. Such an increase in the availability of baclofen is concerning. This study aimed to determine the change in number and profile of self-poisoning with baclofen over time, as baclofen has become increasingly popular, in order to describe the severity of self-poisoning with baclofen and to focus on co-existing alcohol use disorders, and psychiatric illnesses determine predictors of severity. This was a retrospective study of self-poisoning with baclofen as reported by the western France Poison Control Center (PCC), which represents a population of more than 12 million people from January 2008 to March 2014. One hundred and eleven cases of self-poisoning with baclofen were reported to the western France PCC (62 males and 49 females; average age 39 ± 12). Poisoning severities were as follows: 'null' (nine cases), 'minor' (37 cases), 'moderate' (19 cases) and 'high' (46 cases, including four deaths). The most frequently reported symptoms were neurological (45%) and cardiovascular (27%). The severity was significantly associated with psychiatric disorders (OR = 2.9; p = 0.03). Baclofen, prescribed in high doses, may lead to severe poisoning, particularly in patients with psychiatric illnesses. Authorities should put forward a new policy for prescribing the drug as a treatment for alcohol dependence.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011039 Poison Control Centers Facilities which provide information concerning poisons and treatment of poisoning in emergencies. Centers, Poison Control,Center, Poison Control,Control Centers, Poison,Poison Control Center
D002318 Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM. Adverse Cardiac Event,Cardiac Events,Major Adverse Cardiac Events,Adverse Cardiac Events,Cardiac Event,Cardiac Event, Adverse,Cardiac Events, Adverse,Cardiovascular Disease,Disease, Cardiovascular,Event, Cardiac
D005260 Female Females
D005602 France A country in western Europe bordered by the Atlantic Ocean, the English Channel, the Mediterranean Sea, and the countries of Belgium, Germany, Italy, Spain, Switzerland, the principalities of Andorra and Monaco, and by the duchy of Luxembourg. Its capital is Paris. Corsica,Saint Pierre and Miquelon,Miquelon and Saint Pierre,Miquelon and St. Pierre,St. Pierre and Miquelon
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000437 Alcoholism A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4) Alcohol Abuse,Alcoholic Intoxication, Chronic,Ethanol Abuse,Alcohol Addiction,Alcohol Dependence,Alcohol Use Disorder,Abuse, Alcohol,Abuse, Ethanol,Addiction, Alcohol,Alcohol Use Disorders,Chronic Alcoholic Intoxication,Dependence, Alcohol,Intoxication, Chronic Alcoholic,Use Disorders, Alcohol
D001418 Baclofen A GAMMA-AMINOBUTYRIC ACID derivative that is a specific agonist of GABA-B RECEPTORS. It is used in the treatment of MUSCLE SPASTICITY, especially that due to SPINAL CORD INJURIES. Its therapeutic effects result from actions at spinal and supraspinal sites, generally the reduction of excitatory transmission. Baclophen,Chlorophenyl GABA,Apo-Baclofen,Atrofen,Ba-34,647,Ba-34647,Baclofen AWD,Baclofène-Irex,Baclospas,CIBA-34,647-BA,Clofen,Gen-Baclofen,Genpharm,Lebic,Lioresal,Liorésal,Nu-Baclo,PCP-GABA,PMS-Baclofen,beta-(Aminomethyl)-4-chlorobenzenepropanoic Acid,beta-(p-Chlorophenyl)-gamma-aminobutyric Acid,AWD, Baclofen,Apo Baclofen,ApoBaclofen,Ba34,647,Ba34647,Baclofène Irex,BaclofèneIrex,CIBA34,647BA,GABA, Chlorophenyl,Gen Baclofen,GenBaclofen,Nu Baclo,NuBaclo,PMS Baclofen,PMSBaclofen

Related Publications

David Boels, and Caroline Victorri-Vigneau, and Marie Grall-Bronnec, and Ali Touré, and Anais Garnier, and Alain Turcant, and Gaël Le Roux
October 2017, Basic & clinical pharmacology & toxicology,
David Boels, and Caroline Victorri-Vigneau, and Marie Grall-Bronnec, and Ali Touré, and Anais Garnier, and Alain Turcant, and Gaël Le Roux
April 2017, Clinical toxicology (Philadelphia, Pa.),
David Boels, and Caroline Victorri-Vigneau, and Marie Grall-Bronnec, and Ali Touré, and Anais Garnier, and Alain Turcant, and Gaël Le Roux
September 2015, Alcoholism, clinical and experimental research,
David Boels, and Caroline Victorri-Vigneau, and Marie Grall-Bronnec, and Ali Touré, and Anais Garnier, and Alain Turcant, and Gaël Le Roux
January 2018, Frontiers in psychiatry,
David Boels, and Caroline Victorri-Vigneau, and Marie Grall-Bronnec, and Ali Touré, and Anais Garnier, and Alain Turcant, and Gaël Le Roux
February 1986, Ugeskrift for laeger,
David Boels, and Caroline Victorri-Vigneau, and Marie Grall-Bronnec, and Ali Touré, and Anais Garnier, and Alain Turcant, and Gaël Le Roux
February 1987, Critical care medicine,
David Boels, and Caroline Victorri-Vigneau, and Marie Grall-Bronnec, and Ali Touré, and Anais Garnier, and Alain Turcant, and Gaël Le Roux
November 1972, Lancet (London, England),
David Boels, and Caroline Victorri-Vigneau, and Marie Grall-Bronnec, and Ali Touré, and Anais Garnier, and Alain Turcant, and Gaël Le Roux
December 1972, Lancet (London, England),
David Boels, and Caroline Victorri-Vigneau, and Marie Grall-Bronnec, and Ali Touré, and Anais Garnier, and Alain Turcant, and Gaël Le Roux
January 2010, Current pharmaceutical design,
David Boels, and Caroline Victorri-Vigneau, and Marie Grall-Bronnec, and Ali Touré, and Anais Garnier, and Alain Turcant, and Gaël Le Roux
March 2010, CNS & neurological disorders drug targets,
Copied contents to your clipboard!